Prime Editing Reverses Symptoms of Childhood Neurological Disease
Prime Editing Shows Promise in Treating Devastating Childhood Brain Disease
Table of Contents
Alternating Hemiplegia of Childhood (AHC) is a rare and debilitating neurological disorder that typically begins in early childhood, causing episodes of paralysis, movement disorders, and developmental delays.Now, a groundbreaking study offers a beacon of hope, demonstrating the prosperous use of prime editing – a revolutionary gene editing technology – to treat AHC in mouse models.The research, conducted by a team at the Broad Institute of MIT and Harvard, in collaboration with The Jackson Laboratory, not only alleviated symptoms in the animals but also lays the foundation for potential therapies for a wide range of rare genetic brain diseases.
A New Approach to Gene Editing: Prime Editing
Customary gene editing techniques, like CRISPR-Cas9, frequently enough work by cutting both strands of DNA, which can sometimes lead to unintended consequences. Prime editing, developed by David Liu and his team at the Broad Institute, offers a more precise approach. It acts like a “molecular word processor,” rewriting genetic code directly within the cell without making complete DNA cuts. this minimizes the risk of off-target effects and expands the possibilities for correcting genetic mutations.
“This effort was really about creating a blueprint that could be rapidly applied to other rare diseases too,” explained Terrey of The Jackson Laboratory.
Correcting the AHC Mutation and Restoring Function
the root cause of AHC in many patients lies in mutations within the ATP1A3 gene,which provides instructions for making a protein crucial for nerve cell function. Researchers first validated their prime editing strategy in cells cultured from AHC patients. remarkably,they achieved successful repair of the ATP1A3 mutations in up to 90% of treated cells,with minimal unintended alterations to the genome.
to test the treatment’s efficacy in vivo, the team collaborated with Jackson Lab researchers and utilized two mouse models carrying ATP1A3 mutations mirroring those found in human AHC patients. Untreated mice exhibited the hallmark symptoms of the disease – seizures, movement problems – and experienced premature death. Though, following a single injection of the prime editing system directly into the brain, the treated mice showed dramatic improvements.
Symptoms either disappeared entirely or were considerably reduced. Treated mice lived more then twice as long as their untreated counterparts. Crucially, the function of the Atp1a3 protein was restored, leading to the amelioration of both motor and cognitive deficits. The delivery of the prime editors was achieved using Adeno-Associated Viruses (AAVs), clinically validated vectors already employed in FDA-approved gene therapies for brain disorders.
“The results really exceeded our expectations,” said Sakai. “It was incredibly exciting to see that data.”
Prime Editing Outperforms Traditional Gene Therapy
Interestingly, the researchers also tested traditional gene therapy, which involves delivering a healthy copy of the ATP1A3 gene. Unlike prime editing,this approach failed to improve symptoms in the animal models.this finding underscores the unique advantage of prime editing: its ability to directly correct the disease-causing mutation, rather than simply adding a functional copy of the gene.
“Before this study, we didn’t even know if we could intervene in AHC after birth in an animal,” said Sousa.”Now we know you can.”
A Template for Future Therapies
while the current treatment requires direct brain injection shortly after birth, the team is actively investigating less invasive delivery methods and exploring the potential for effective treatment even later in life. The broader implications of this research extend far beyond AHC. The team envisions their approach as a versatile template for tackling other rare genetic diseases, notably those affecting the brain.
The ability to rapidly design and test multiple gene editing treatments together promises to accelerate the development of precision therapies for a multitude of conditions. This study represents a meaningful step forward in the field of gene editing and offers renewed hope for individuals and families affected by rare genetic disorders.
“This is a powerful proof of concept,” said Sakai.”It shows that we can use prime editing to treat genetic brain diseases, and it lays the groundwork for translating this approach to the clinic.”
Sources: